238 related articles for article (PubMed ID: 20368556)
21. The importance of test positive predictive value in ovarian cancer screening.
Greene MH; Feng Z; Gail MH
Clin Cancer Res; 2008 Nov; 14(22):7574; author reply 7577-9. PubMed ID: 18948386
[No Abstract] [Full Text] [Related]
22. The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
Karlan BY; McIntosh M
J Clin Oncol; 2007 Apr; 25(11):1303-4. PubMed ID: 17416848
[No Abstract] [Full Text] [Related]
23. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
24. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
[TBL] [Abstract][Full Text] [Related]
25. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
26. Screening and detection of ovarian cancer.
Breedlove G; Busenhart C
J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
[TBL] [Abstract][Full Text] [Related]
27. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
28. [Increased level of carcinoembryonal antigen is not primarily a marker for ovarian cancer].
Kristensen CA; Roed HM
Ugeskr Laeger; 2005 Jan; 167(2):189; author reply 190. PubMed ID: 15697136
[No Abstract] [Full Text] [Related]
29. Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer.
Senapad S; Neungton S; Thirapakawong C; Suphanit I; Hangsubcharoen M; Thamintorn K
Anticancer Res; 2000; 20(2B):1297-300. PubMed ID: 10810438
[TBL] [Abstract][Full Text] [Related]
30. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
[TBL] [Abstract][Full Text] [Related]
31. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
32. [Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].
Lapchenkov VI; Dudarev AL; Vinokurov VL; Iurkova LE; Barbanel EIu
Vestn Rentgenol Radiol; 1993; (5):30-1. PubMed ID: 7801580
[TBL] [Abstract][Full Text] [Related]
33. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic markers for ovarian cancer screening: not ready for routine clinical use.
Coates RJ; Kolor K; Stewart SL; Richardson LC
Clin Cancer Res; 2008 Nov; 14(22):7575-6; author reply 7577-9. PubMed ID: 18948387
[No Abstract] [Full Text] [Related]
35. Validation of serum biomarkers for detection of early-stage ovarian cancer.
Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
37. [Biomarker in gynecologic malignancies].
Isonishi S
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
39. [Mass-screening for ovarian cancer].
Sato S; Higuchi T; Yokoyama Y; Sakamoto T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():601-4. PubMed ID: 15535316
[No Abstract] [Full Text] [Related]
40. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
